Lu AA24493 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich's Ataxia
Conditions
Friedreich's Ataxia
Trial Timeline
Oct 1, 2009 → Apr 1, 2011
NCT ID
NCT01016366About Lu AA24493 + Placebo
Lu AA24493 + Placebo is a phase 2 stage product being developed by Lundbeck for Friedreich's Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT01016366. Target conditions include Friedreich's Ataxia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01016366 | Phase 2 | Completed |
Competing Products
11 competing products in Friedreich's Ataxia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Interferon γ-1b | Amgen | Phase 3 | 76 |
| interferon γ-1b | Amgen | Phase 3 | 76 |
| Interferon γ-1b + Placebo | Amgen | Phase 3 | 76 |
| varenicline + placebo | Pfizer | Phase 2/3 | 64 |
| Omeveloxolone | Biogen | Pre-clinical | 20 |
| Placebo + EPI-743 400 mg + EPI-743 200 mg | PTC Therapeutics | Phase 2 | 49 |
| SGT-212 | Solid Biosciences | Phase 1 | 25 |
| idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone + Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |